Abstract:Title. Androgen Receptor Protein Degraders Patent Publication Number. WO 2020/142228 A1 Publication Date. July 09, 2020 Priority Application. US 62/788,005 Priority Date. January 03, 2019 Inventors.Wang, S.; Han, X.; Wang, C.; Qin, C.; Xiang, W.; Xu, T.; Yang, C. Assignee Company. The Regents of the University of Michigan [US/US]; Office of Technology Transfer, 1600 Huron Parkway, second Floor, Ann Arbor, MI 48109−2590 (US). Disease Area. Prostate cancer (PCa) Biological Target. Androgen receptor Summary. Androgens are a class of steroid hormones that consist of natural or synthetic steroid hormone derivatives of cholesterol, which play a role in the development and maintenance of male characteristics. They function primarily through androgen receptor (AR) signaling and are recognized as a key driver of prostate cancer (PCa) growth and survival. The AR is a 110 kDa protein with sequence homology that is shared with other nuclear hormone receptors in the superfamily such as the progesterone receptor (PR), estrogen receptor (ER), and glucocorticoid receptor (GR). Furthermore, the AR consists of four basic elements: the N-terminal domain, DNA binding domain, hinge region, and ligand binding domain (LBD). The centrally located DNA binding domain consists of two zinc finger domains that recognize a specific DNA sequence and is the most highly conserved region. Whereas, the LBD forms the ligand-binding pocket that contains ligand-dependent activation function 2 (AF-2) and mediates interactions between the AR, heat shock proteins, and motifs located within the N-terminal domain. PCa remains themost common cancer and the second leading cause of cancer-related deaths inmen. However, if detected early the current arsenal of therapeutic options provide a promising chance for long-term survival, though ∼40% of patients will develop castration-resistant PCa. Androgen deprivation therapy (ADT) remains the primary treatment regimen for patients who demonstrate biochemical relapse and those that are challenged with locally advanced or metastatic disease. In some cases, the disease ultimately progresses to a lethal form despite castrating levels of testosterone and is termed metastatic castrationresistant prostate cancer (mCRPC). Most often, mCRPC is characterized by rising serum levels of prostate-specific antigen (PSA) after the restoration of the AR transcriptional activity. Consequently, the standard of care for patients with mCRPC after ADT treatment involves sustained AR inhibition that competitively bind the ligand-binding domain (LBD) of the AR or CYP17A1 inhibitors. Mutation in the AR LBD as well as active AR-splice variants that lack the LBD have been associated with primary and acquired resistance. Consequently, a new therapeutic approach is needed in the treatment of PCa and related diseases associated with the AR. The present Patent Highlight showcases heterobifunctional small molecules that are androgen receptor (AR) protein degraders useful for the treatment of a variety of diseases including prostate cancer. The Proteolysis Targeting Chimera (PROTAC) strategy consists of a heterobifunctional small molecule containing one ligand that binds to the target protein of interest (AR) and a second ligand for an E3 ligase system, tethered together by a chemical linker. Thus, AR degraders designed based upon the PROTAC concept may be effective for the treatment of CRPC when the disease becomes resistant to AR antagonists or to androgen synthesis inhibitors.

Abstract 2898: Development of the lipid kinase PIKfyve PROTAC degrader against neuroendocrine prostate cancer

Abstract 3299: Harnessing PIKfyve as a therapeutic vulnerability in neuroendocrine prostate cancer

PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

Abstract 1001: Functional and Mechanistic Interrogation of Androgen Receptor Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer

Abstract 6048: Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader

Abstract LB133: An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer

Abstract 1960: Targeted Androgen Receptor (AR) Protein Degradation for the Treatment of Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment

Abstract 1231: First-in-class AR-V7/AR-fl small molecule molecular glue degrader for prostate cancer treatment

Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.

Abstract 4514: Discovery of potent and orally bioavailable degraders of HPK1 based on a novel HPK1 binder

Developing selective PI3K degraders to modulate both kinase and non-kinase functions

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Abstract 4504: Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer

Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.

Abstract 4505: Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy

Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells

Abstract 3426: Catalytic degraders effectively address kinase site mutations in EML-ALK oncogenic fusions

Abstract C033: Targeting PIKfyve-driven lipid metabolism in pancreatic cancer

Strategies Toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.